Home・Lista de Ações・AbCellera Biologics Inc

AbCellera Biologics Inc

Fechado

SetorSaúde

6.4 4.23

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.71

Máximo

6.55

Indicadores-chave
By Trading Economics
Rendimento	-34M -43M
Vendas	-37M 8.3M
EPS	-0.14
Margem de lucro	-519.122
Funcionários	562
EBITDA	-23M -41M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+82.94% upside

Dividendos
By Acuity
Próximos Ganhos	5 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	178M 1.8B
Abertura anterior	2.17
Fecho anterior	6.4

Sentimento de Notícias

By Acuity

47%

53%

159 / 340 Ranking em Healthcare

AbCellera Biologics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de ago. de 2026, 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

5 de ago. de 2026, 23:02 UTC

Social Media

News

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

3 de ago. de 2026, 19:36 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

31 de jul. de 2026, 19:33 UTC

Correlated Moves

Social Media

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

30 de jul. de 2026, 23:41 UTC

Correlated Moves

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

29 de jul. de 2026, 23:51 UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

28 de jul. de 2026, 19:41 UTC

News

Abcellera Biologics is rising, driven by gains in the Life Sciences Tools & Services sector and positive trends in the antibody therapeutics market.

27 de jul. de 2026, 19:46 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher, reflecting a modest increase since Friday's close. Broader market gains may influence sentiment in life sciences.

24 de jul. de 2026, 23:46 UTC

Abcellera Biologics Inc shares are higher in after-market hours, showing resilience despite recent challenges in the bond market and declining prices.

22 de jul. de 2026, 20:06 UTC

Abcellera Biologics Inc shares are lower today, reflecting broader market trends amid uncertainty ahead of the Federal Reserve meeting on July 29.

21 de jul. de 2026, 23:06 UTC

Correlated Moves

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

20 de jul. de 2026, 23:16 UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.

Comparação entre Pares

Variação de preço

AbCellera Biologics Inc Previsão

Preço-alvo

By TipRanks

82.94% parte superior

Previsão para 12 meses

Média 10.83 USD 82.94%

Máximo 13 USD

Mínimo 7 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para AbCellera Biologics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para AbCellera Biologics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

159 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.